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The arenaviruses include a number of important pathogens including Lassa virus and Junin virus. Presently, the only treatment
is supportive care and the antiviral Ribavirin. In the event of an epidemic, patient triage may be required to more eﬀectively
manage resources; the development of prognostic biomarker signatures, correlating with disease severity, would allow rational
triage. Using a pair of arenaviruses, which cause mild or severe disease, we analyzed extracts from infected cells using SELDI mass
spectrometry to characterize potential biomarker proﬁles. EDGE analysis was used to analyze longitudinal expression diﬀerences.
Extracts from infected guinea pigs revealed protein peaks which could discriminate between mild or severe infection and between
times post-infection. Tandem mass-spectrometry identiﬁed several peaks, including the transcriptional regulator prothymosin-α.
Further investigation revealed diﬀerences in secretion of this peptide. These data show proof of concept that proteomic proﬁling
of host markers could be used as prognostic markers of infectious disease.
1.Introduction
Viral hemorrhagic fevers (VHFs) represent an important
class of emerging diseases and are classiﬁed as category
A priority pathogens by the National Institute for Allergy
and Infectious Diseases. The VHFs Lassa fever and the
Argentine, Bolivian, Venezuelan, and Brazilian hemorrhagic
feversarecausedbymembersoftheArenaviridae[1].Despite
their status as emerging infectious diseases, little is known
about the molecular basis of the pathology of these diseases,
and this has hindered the design of antiviral therapeutics.
Arenavirus pathogenesis is believed to involve the dysregu-
lation of cytokines; for example, infection with the virulent
Lassa virus (LASV) prevents macrophage activation and
TNF-α production, whereas infection with the avirulent
Mopeia virus induces proinﬂammatory cytokine production
[2], a similar eﬀect has been shown with attenuated and
virulent isolates of Pichind´ ev i r u s(PICV) [3]; proteomic
and kinomic level analyses have also shown diﬀerential
cell signaling events induced by attenuated and virulent
arenavirus infection [4–6].
Currently, the only drug used in the treatment of these
infections is the broad-spectrum antiviral, Ribavirin,w h i c h
requires administration within the ﬁrst week of infection to
bemosteﬃcacious[7].Asonlyasmallproportionofpatients
infected with LASV develop a hemorrhagic fever, indicators2 Journal of Biomedicine and Biotechnology
of prognosis will be critical in the eﬃcient management
of healthcare resources during epidemics. Currently, the
best prognostic marker for severe disease is viral load, with
high levels of virus correlating with increased likelihood of
severe disease [8]. However, quicker methods of prognosis
determinationwouldbeofsigniﬁcantuseinaclinicalsetting.
We have previously used surface-enhanced laser des-
orption ionization time-of-ﬂight (SELDI-TOF) mass spec-
trometry to characterize proteins bound to a thioaptamer
(oligonucleotides with thiophosphate backbone substitu-
tions) on a ProteinChip array [9]. SELDI is a high-
throughput proﬁling platform that combines retentive chro-
matography and mass spectrometry in one platform REFS.
The process involves selective extraction and retention of
proteins on chromatographic chip surfaces arranged in
an array of spots and their subsequent analysis by mass
spectrometry.
In this study, we have used SELDI-TOF to compare
cell extracts for representative protein “signatures” following
infection. PICV is a genetically characterized model for
Lassa fever and recent construction infectious clones may
allow the role of individual sequence changes in determining
pathogenesis to be elucidated [10, 11]. Using two variants of
PICV, P2, which causes a mild, self-limiting infection, and
P18, which causes a lethal hemorrhagic disease [12], we can
identify signatures unique to mild and severe infection, and
which reﬂect common responses.
In this report, we describe the host-cell protein “signa-
tures” following mock, P2, and P18 PICV infection over
time. We show that, consistent with previous data from
several groups, the virulent variant more closely resem-
bles mock-infection, suggesting a suppression of cellular
responses to infection [2, 5, 13]. In addition, we identify
one of these protein peaks by tandem mass spectrometry as
prothymosin-α, which may indicate a potential therapeutic
target for the treatment of hemorrhagic arenavirus infection.
2.MaterialsandMethods
2.1.CellCultureandViruses. Murinemonocyte-likeP388D1
cells were maintained in RPMI supplemented with 5% fetal
bovine serum and 5mM glutamine. Cells were cultured
in the absence of antibiotics to ensure no underlying
contamination. Cells were infected in triplicate with PEG
puriﬁed P2 or P18 PICV at a multiplicity of infection
of 5 or mock infected with virus puriﬁcation medium.
Cells were harvested at 8 timepoints and cytoplasmic and
nuclear extracts prepared. For animal experiments, male
Hartleyguineapigswereinfectedintraperitoneallywith1000
plaque forming units of the P2 or P18 variant of PICV
or mock-infected with phosphate buﬀered saline (n = 7
per group/timepoint) and sacriﬁced at 1 and 6 days post
infection. Animal experiments were performed following
institutional animal care and use approved guidelines and
protocols.
2.2. Cytoplasmic and Nuclear Fractionation of Cells. Cells
were fractionated into cytoplasmic and nuclear fractions as
previously described [14] with the addition of a nuclear
puriﬁcationstepusingOptiprep(Axis-Shield,Oslo,Norway)
gradients. Brieﬂy, lysates were underlayered with 10mL 30%
Optiprep and 5mL 35% Optiprep and centrifuged at 4◦C
for 30 minutes at 4300 × g. The interface was removed
and placed in a fresh tube which was ﬁlled with sucrose
buﬀer I (described in Dyer & Herzog, 1995) plus 1.5mM
CaCl2. Following centrifugation at 4◦Cf o r1 5m i n u t e sa t
1900 × g, the pellet was resuspended in sucrose buﬀer I
and the centrifugation repeated. Nuclear lysis was completed
following the referenced protocol.
2.3. Fractionation of Cytoplasmic Portion of P388D1 Cells.
5.4mL buﬀer containing 10mM Tris and 9M urea (pH
9) was added to 2.7mL combined cytoplasmic portion
of mock-, P2-, and P18-infected macrophages, and the
mixture was incubated at 4◦C for 20 minutes. It then was
dialyzed against 50mM Tris (pH 8), after which the dialyzed
solution was added to 30μLp a c k e dQH y p e r DFb e a d s( P a l l
corporation, PA), and incubated for 30 minutes at 4◦C. The
beads were collected by centrifugation (3000 × g, 1 minutes)
and the supernatant was saved as ﬂow-through. The proteins
bound to the beads were eluted by lowering the pH of the
buﬀerinﬁvefractions(90μLofeacheluentin50mMofeach
pH buﬀer): Q1 (pH 6.5), Q2 (pH 5.5), Q3 (pH 4), Q4 (pH
3) and Q5 (pH 3 + 1M NaCl). 10μLo fe a c hf r a c t i o nw a s
added to 90μL5 0m MT r i s( p H8 )b u ﬀer and was captured
on Q10 anion exchange ProteinChip array surfaces (Bio-
RadLaboratories,Hercules,CA)withabioprocessorBiomek
3000 (Beckman Coulter, Fullerton, CA).
2.4. SELDI-TOF Mass Spectrometry and Spectral Analysis.
The mass spectra of the proteins captured on Q10 chips were
recorded on the PCS 4000 ProteinChip array reader (Bio-
Rad laboratories, Hercules, CA). Experiments were run in
triplicate at the 8 time points mentioned above, leading to
a total of 72 samples each for the cytoplasmic and nuclear
fractions. SELDI spectra were recorded on the PCS4000
ProteinChip System at a laser intensity setting of 2600.
Spectra were analyzed with the Ciphergen Express (CE)
software.Analysiswaslimitedtothemolecularweight(MW)
range 2kDa–20kDa. Peak intensities were scaled using CE.
2.5. Statistical Analysis. Log-transformed peak intensity val-
ues were subjected to a 2-way ANOVA test with Matlab
v. R2007a (The Mathworks, Natick, MA). P-values were
calculated for three null hypotheses: (a) that all samples
from the Mock, P2, and P18 infections came from the same
population, (b) that all samples from the eight diﬀerent time
points came from the same population, and (c) that the
eﬀectsduetothetwofactors,infectionandtime,areadditive.
Spotﬁre DecisionSite 9.0 (TIBCO Software Inc., Palo
Alto, CA) was used for hierarchical clustering (HC) to group
the biomarkers detected by the timecourse analysis described
above. SELDI peak intensities were ﬁrst Z-score normalized
and HC was then run using the unweighted average method,
withEuclideandistanceasthesimilaritymeasureandaverage
value as the ordering function. Following HC, PrincipalJournal of Biomedicine and Biotechnology 3
Components Analysis (PCA) was performed transforming
the data into a small number of dimensions to visualize the
clustering of the biomarkers.
We also analyzed data using “Extraction of Diﬀerential
Genomic Expression” (EDGE) as this technique is designed
for the analysis of timecourse data [15, 16]. The method
builds on the false-discovery rate (FDR) developed by
Benjamini and Hochberg to control the expected proportion
of falsely rejected null hypotheses [17]. For the multiple
signiﬁcance testing performed in the analysis of-omics data,
the Q-values provide a more meaningful and practical
measure than the P-value [18]. Appropriate cutoﬀsa r e
imposed on the Q-value to control the desired proportion
of falsely rejected hypotheses.
2.6. Protein Identiﬁcation and Veriﬁcation. The cytoplasmic
samples were treated with 9M urea to denature the proteins,
fractionated by Q HyperD F beads, and eluted into ﬂow-
through (FT), and ﬁve pH factions at pH 6.5, 5.5, 4.0, 3.0,
and pH 3 + 1M NaCl. The fractions were captured on Q10
chips.Thechipwasloadedonthehigh-resolutionQSTARXL
spectrophotometer and data collection was performed. The
fragment masses were used as probes to search the mouse
protein database for protein identiﬁcation.
2.7. Biomarker Identiﬁcation Using SELDI Quadrupole Time
of Flight Tandem Mass Spectrometry. Tandem mass spectro-
metric peptide sequencing was accomplished using QSTAR
XL (Applied Biosystems Inc., Foster City, CA) quadrupole
time of ﬂight instrument equipped with Ciphergen Pro-
teinChip Interface PCI 1000. The instrument was calibrated
externally using the known MS/MS spectrum of ACTH
peptide (1–24) at 2465.2m/z, where four fragment ions and
the parent ion were used as calibration points. All mass
spectra were acquired in positive ion mode with collision
energythatfollowstheruleofapproximate50eV/kDaparent
peptide mass. Raw data were analyzed using the instru-
ment’s software. Fragmentation information from tandem
MS spectrum was ﬁrst submitted to the sequence query
programinMatrixScience(http://www.matrixscience.com/)
for possible identities with a precision tolerance of 0.4Da for
MS/MS fragments and 70ppm for the parent peptide.
2.8. Veriﬁcation of the Identiﬁed Biomarkers. 60uL of packed
protein G agarose beads (Santa Cruz Biotechnology, CA)
were incubated with 30uL mouse monoclonal antibody
against prothymosin alpha (Alexis Biochemicals, CA) for 1
hour at 4C, followed by three times wash of 1XPBS, 50uL
combined cytoplasmic portion of mock-, P2-, and P18-
infected macrophages was then added to the beads, and the
solution was incubated at 4C for 2 hours, followed by three
times wash of 1XPBS + 0.1% Triton X-100. After a brief
wash with water, proteins bound to the antibody against
prothymosin alpha were eluted with 60uL of elution buﬀer
containing 0.3% TFA and 50% acetonitrile. The eluant was
analyzed by PCS 4000 ProteinChip array reader (Bio-Rad
laboratories, Hercules, CA).
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Figure 1: SELDI spectra reveal virus and time-based peak diﬀer-
ences. Guinea pigs were mock-infected or infected with the P2 or
P18 variant of Pichinde virus. At 1 day and 6 days post infection,
peritonealcellswereharvestedandcytoplasmicandnuclearextracts
prepared and analyzed using surface enhanced laser desorption
ionization time-of-ﬂight mass spectrometry. Experiments were
performedintriplicate.Proteinpeakswereidentiﬁedwhichshowed
patterns speciﬁc to type and stage of infection. The ﬁgure shows a
representative set of spectra from cytoplasmic extracts.
2.9. Enzyme-Linked Immunosorbant Assay. Supernatants
from infected triplicate cultures were added to 96-well plates
in triplicate wells (Nunc) and incubated overnight at 4◦C.
Wells were then blocked with 5% w/v bovine serum albumin
for 1 hour. Primary antibody (antiprothymosin-α1,S a n t a
Cruz,SantaCruz,CA,1/2000)wasaddedtowellsinblocking
solution and incubated for 2 hours. Wells were then washed
four times in phosphate buﬀered saline + 0.05% tween-20
for 5 minutes prior to incubation with secondary antibody
(anti-rabbit Ig HRP conjugate, 1/2000) in blocking solution
for 1 hour. Wells were washed as before and levels of
[pro] thymosin are indirectly assayed by the addition of the
colorimetric substrate TMB (Sigma, St Louis, MO).
3. Results
3.1. SELDI Mass Spectrometry of Guinea Pig Peritoneal Cells.
Peritoneal cell extracts from infected guinea pigs were
analyzed by surface enhanced laser desorption ionization
(SELDI) mass spectrometry (Figure 1). Peaks were identiﬁed
that could discriminate between type of infection (e.g.,
Figure 1, box A) and stage of infection (e.g., Figure 1,b o x
B). Consistent with our previous ﬁndings, infection with the
virulent P18 variant of the virus resulted in a spectrum that
more closely resembled mock infection than infection with
the attenuated P2 virus.4 Journal of Biomedicine and Biotechnology
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Figure 2: Diﬀerential intensity of prothymosin-α peak. SELDI mass spectrometry analysis of triplicate cytoplasmic extracts from mock-,
P2-,orP18PICV-infectedP388D1cellsoveratimecourseofinfectionshowsdiﬀerentialintensityofaproteinpeak(indicatedbythearrows)
at m/z approximately 3790 (Q = 0.0164). This peak was identiﬁed as prothymosin-α by tandem mass spectrometry. The ﬁgure shows one
representative set of spectra from three independent experiments.
We next infected triplicate cultures of murine P388D1
macrophage-like cells for a timecourse of infection from 15
minutesto16hours.Weusedacelllineforthisstudyinorder
to increase the sample quantity for downstream assays and
database searching for identiﬁcation by mass spectrometry.
We have previously used this cell line to investigate PICV-
hostinteractionsandarefamiliarwithhowcellularresponses
in this cell line model those seen in primary guinea pig
macrophages. Triplicate nuclear and cytoplasmic samples
were prepared following mock-infection or infection with
P2 or P18 PICV at 15m, 30m 1, 2, 4, 8, 12, and 16
hours post infection. Samples were analyzed by SELDI mass
spectrometry. Statistical analysis by ANOVA and EDGE
identiﬁed27and35signiﬁcantlydiﬀerentpeaks,respectively.
Hierarchical cluster analysis revealed similarities in peak
patterns between P2 and P18 infection at late times (12
and 16 hours) post infection (data not shown), but that
P18 was most similar to mock infection at early times
post infection, consistent with our previous results. We
next selected several signiﬁcant peaks for identiﬁcation
by mass spectrometry. We identiﬁed several peaks as two
SH3-domain binding proteins, stathmin, prothymosin-α,
thioredoxin, and various ribosomal proteins. Prothymosin-
α was identiﬁed as a signiﬁcantly diﬀerentially expressed
p r o t e i np e a kw i t ha n dE D G EQ value of 0.0164. We have
previously identiﬁed prothymosin-α as a node in a signaling
network constructed following kinomics analysis of PICV-
infected cells [5] and so was selected for additional study.
3.2. Veriﬁcation of the 3787 Peak as Prothymosin-α from On-
Chip Digestion and MS/MS. The pattern of prothymosin-α
peak expression in a representative sample of cytoplasmic
extracts is shown in Figure 2. Lower peak intensity following
infectionwithP18PICVcanbeseenat1,2,and4hourspost-
infection. However, prothymosin-α can shuttle between theJournal of Biomedicine and Biotechnology 5
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Figure 3: Identiﬁcation and validation of peak 3790 as prothymosin-α. Mass spectrum of proteins from fraction Q3 that bound to Q10
ProteinChip array and was analyzed on QSTAR XL instrument (mass range from 1000 to 4000m/z).
cytoplasm and the nucleus where it functions as a histone
H1 binding protein and is associated with cell growth [19–
21]. Prothymosin-α and the peptide thymosin-α1,p r o d u c e d
by proteolytic processing of prothymosin-α and an immune-
modulator, can also be secreted [22–24]; for these reasons,
the changes in peak intensities may not reveal the functional
changesandeﬀectsinprothymosin-αactivityandregulation.
In order to verify the marker with molecular mass at
3787Da, the cytoplasmic portion of the combined mock-,
P2-, and P18-infected macrophages was fractionated on
Q HyperD F beads with six fractions including the ﬂow-
through; each fraction was further captured on Q10 Protein
Chip array surfaces. The marker protein was highly enriched
in Q3 fraction on Q10 array surfaces (data not shown).
The molecular mass of the marker is only 3787 Da; since
the QSTAR XL instrument can analyze parent ion up to
5400m/z, the peak could be identiﬁed as prothymosin-α
without any further puriﬁcation (Figure 3). The MS/MS
spectrum is shown in Figure 4(a). We conﬁrmed the iden-
tiﬁcation of prothymosin-α using immunoprecipitation.
Protein G agarose beads coupled to a monoclonal antibody
against prothymosin alpha were used to immunoprecipitate
prothymosin-α from extracts; the same protein peak at
3787Da was identiﬁed (Figure 4(b)).
3.3. Veriﬁcation of Protein Identiﬁcation and (Pro)Thymosin-
α Secretion. Prothymosin-α contains the secreted peptide
thymosin-α1 [25–27]. We harvested supernatants from
triplicate infected cultures over a 16-hour timecourse of
infection and assayed the levels of (pro)thymosin-α in
the supernatants (Figure 4(a)). As the thymosin peptide is
contained within prothymosin-α, we are unable to distin-
guish between these peptides. Infection with the attenuated
P2 variant of PICV induced consistently higher levels of
(pro)thymosin-α in supernatants than mock infection or
infection with the virulent P18 variant, ranging a 2–2.5-fold
increase over baseline (mock-infected) levels (Figure 5(a)).
Levels of secreted (pro)thymosin-α were signiﬁcantly higher
(P<. 05) from 15 minutes to 8 hours postinfection.
Consistent with many of the signiﬁcant peaks in the SELDI
analysisandmanyofourpreviousobservations,theresponse
induced by P18 infection more closely resembled mock-
infection than infection with P2 PICV [3–5], although P18
did begin to induce higher levels of secreted (pro)thymosin-
α than mock-infection at late times postinfection.
We infected triplicate cultures of P388D1 cells with P2 or
P18 PICV or mock infected with PEG puriﬁcation medium
and prepared whole cell extracts at 24 hours post infection.
Stathmin expression was assayed by immunoblot. Stathmin
expression was signiﬁcantly reduced in both P2 and P18
infected cells compared to mock, with P18 infection showing
reducedstathminexpressioncomparedtoP2acrosstriplicate
experiments (Figure 5(b)). Stathmin expression is controlled
by a number of transcription factors, including a signaling
module based around NF-κB, AP-1, c-Myc, and p53, which6 Journal of Biomedicine and Biotechnology
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Figure 4: (a) The peptide with m/z approximately 3790 was identiﬁed as the fragment of prothymosin alpha by the following MS/MS
microsequencing. (b) Mass spectrum of proteins pulled out from cytoplasmic fraction of murine macrophage samples by antiprothymosin
alpha which was coupled to protein G agarose beads (mass range from 1000 to 20,000m/z). Antiprothymosin alpha-coupled protein G
agarose beads were incubated with cytoplasmic fraction and eluted proteins were analyzed on NP 20 ProteinChip array.
we have previously shown to be diﬀerentially regulated in
PICV infection [4, 5], and which may suggest the molecular
basis for diﬀerential stathmin expression.
4. Discussion
Many virus infections present with nonspeciﬁc ﬂu-like
symptoms complicating diagnosis; additionally, very few
markers exist for determining the prognosis of infection. In
particular cases, such as in the response to an epidemic or
an intentional release, the ability to quickly triage patients on
the basis of likely outcome could play a signiﬁcant role in the
management of what might be limited healthcare resources.
The development of biomarkers that correlate with disease
prognosis would be a valuable clinical tool. Additionally,
certain biomarkers may reveal an underlying mechanism
of pathogenesis. These can feed back into basic research to
identify potential therapies.Journal of Biomedicine and Biotechnology 7
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Figure 5: (a) Induction of (pro)thymosin-α expression by PICV
infection. P388D1 cells were infected with either P2 or P18 PICV
in triplicate and tissue culture supernatants collected at various
times post infection for determination of (pro)thymosin-α levels by
ELISA.Foldincreasesarecomparedtolevelsfromtriplicatesamples
at time = 0 and show the results from three experiments. Error
bars show the standard error of the mean, and asterisks indicate
signiﬁcant (P<. 05) diﬀerences in levels induced between P2
and P18 infection as determined by Student’s t-test. (b) Changes
in stathmin expression following infection by P2 and P18 PICV.
Triplicate cultures of P388D1 cells were infected with PICV and
whole cell lysates assayed or stathmin levels by immunoblotting.
Biological phenomena, such as the progression of viral
infection studied here, are temporal in nature, and the
resulting observations need to be analyzed with statistical
techniques that can reveal temporal diﬀerential expression.
EDGE analysis of our data uncovered 35 diﬀerentially
expressing proteins as compared to 27 by 2-way ANOVA.
Thus our results here indicate for proteomic data, as Storey
et al. (2005) ﬁrst demonstrated with genomic data, that
dynamic methods such as EDGE are more eﬀective at
discovering candidate biomarkers that may be hidden to
static methods. It is worth noting, however, that EDGE
is a univariate method and it examines the data protein
by protein (peak by peak, in the case of the present
method) to evaluate diﬀerential expression. These studies
demonstrate that SELDI mass spectrometry can be used
to determine diﬀerences between attenuated and virulent
virus infection, and that the development of characteristic
diagnostic and prognostic “biomarker signatures” may be
of use in managing these infections. In addition, we have
shown that this approach can be used as a discovery tool
to determine potential mechanisms of pathogenesis and
identify targets for therapeutic intervention at the level of
modulation of the host immune response.
In this model system, we have used two variants of
a PICV which result in a mild infection, from which the
animals recover, or a severe hemorrhagic disease. Further
studies will use only the virulent virus variant and investigate
the diﬀerential responses between animals that succumb to
infection and those which recover. This study represents
an important proof of principle that mass spectrometry
methods can be used to diﬀerentiate between infections
that result in severe disease and those that are self-limiting,
suggesting that diagnostic and prognostic assays can be
developed which function by detecting host responses to
infection, rather than virus material directly. This may allow
the development of assays which can identify the agent of
infection ap r i o r ia n dw h i c hm a yb el e s sp r o n et or e d u c t i o n
of assay sensitivity by viral mutation.
We also identiﬁed diﬀerential secretion of a host
immunomodulatory peptide between infection with atten-
uated and virulent virus variants although we could not
discriminate between prothymosin-α and thymosin-α1 in
this study. As infection with the attenuated virus leads to
a mild-infection and viral clearance, it is likely that the
correct immune signaling events are activated, leading to the
development of protective immunity, events which may be
suppressed in virulent infection. The use of immunomod-
ulation and targeting of the host-responses to, and critical
cellular-factors for, infection may be a viable therapeutic
option in the treatment of infectious disease and may
allow existing drugs to be repositioned [28–32]. Decreased
thymosin-α1 secretion in virulent infection may contribute
to the lack of development of the protective immune
response, potentially through failure of proper induction
of NF-κB, MAP kinase, and MyD88 pathways [33, 34].
Thymosin-α1 is already being tested as a therapeutic against
HIV/AIDS, sepsis, hepatitis B and C viruses, and several
cancers [24, 35–40]. Its characterized pharmacodynamics
and kinetics may facilitate its development as a therapeutic
for emerging infectious diseases.
Prothymosin-α can also function as a transcriptional
regulator. Interestingly, prothymosin-α has been shown to
interactwithcAMPresponseelement-binding(CREB)bind-
ing protein and can stimulate NF-κB and AP-1 driven tran-
scription [41]. We have previously identiﬁed these transcrip-
tion factors as being centrally involved in mediating host-
responses to PICV infection [3–5]. NF-κB and AP-1 have
also been implicated in mediating host-responses to other
Lassa fever models and hemorrhagic fever infections such as
EbolaandRiftValleyfever[42–45]. These pathways have also
suggested further targets for immunomodulatory therapies
[31]. Modulation of CREB binding protein function is the
mechanism used by the A238L protein of the hemorrhagic8 Journal of Biomedicine and Biotechnology
DNA virus African swine fever virus,t om o d u l a t ep r o -
inﬂammatory gene transcription. The protein translocates
to the nucleus and alters CREB binding protein and p300
function, preventing recruitment to enhanceosomes and
inhibiting expression of genes including TNF-α and COX-2
[46–49].
We have used SELDI mass-spectrometry to compare
protein “signatures” following infection of guinea pigs with
attenuated and virulent virus variants. This study demon-
strates proof of principle that proteomic methods can distin-
guish between attenuated and virulent forms of infection in
vivo. We have shown that, consistent with previous studies,
infection with the virulent virus results in responses more
similar to mock-infection, suggesting an inhibition of host
responses. We identiﬁed a peptide-prothymosin-α-which
contains the soluble immune mediator thymosin-α1 as being
diﬀerentially expressed between infections and conﬁrmed
diﬀerential secretion. These studies shed further light on
the mechanisms of hemorrhagic arenavirus pathogenesis,
identify a potential strategy for therapy, and illustrate how
proteomic approaches for biomarker discovery can generate
additional hypotheses for further, targeted investigation.
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